Transcriptional analysis of primary AML patient samples.

Supplementary Table S4 shows the list of custom minipool sgRNA target genes.

Supplementary Table S5 shows the rank order list of genes targeted by sgRNAs enriched in the custom minipool CRISPR/Cas9 knockout screens.

Inhibition of KDM5 enzymes by the (R)- and (S)-enantiomers of 2-hydroxyglutarate.

Characterization of isogenic TF-1 cell lines expressing TET2-targeting shRNAs.

Supplementary Table S1 shows the frequencies of TET2 and IDH mutations in clonal myeloid disorders.

Supplementary Table S7 shows the gene set enrichment analysis gene set that corresponds to Figure 4E.

Genomic regions marked by increased trimethyl-H3K4 are enriched in IDH1-mutant glioma MCTS lines when compared to IDH1-wild-type MCTS lines.

Supplementary Table S3 shows the rank order list of genes targeted by sgRNAs enriched in the genome-wide CRISPR/Cas9 knockout screens.

List of supplementary figures and tables.

5mC levels in primary AML and primary glioma samples and in MCTS lines.

Characterization of isogenic IHA cell lines.

Supplementary Table S9 shows the gene set enrichment analysis gene set that corresponds to Figure S6A.

Supplementary Table S6 shows the mutational profiles of the primary AML patient samples subjected to H3K4me3 ChIP-seq.

Supplementary Table S11 shows the characteristics of the primary glioma patient samples.

Supplementary Table S10 shows the gene set enrichment analysis gene set that corresponds to Figure S6B.

Prolonged exposure to MLL inhibitor VTP50469 does not affect the proliferation of TF-1 cells grown under cytokine-rich conditions.

Characterization of KDM5A mutants.

Supplementary Table S2 shows the quantification of (R)-2HG in TF-1 cells.

Supplementary Table S8 shows the pathway analysis of the expression data from Supplementary Table S7.